About Neurotek
Neurotek is a cognitive performance intelligence company transforming how cognitive function is measured, understood, and used to inform decisions.
Founded to move beyond subjective evaluation
Our technology turns objective cognitive performance data into actionable insights - helping professionals and organizations move beyond subjective evaluation to better understand how people perform, where cognitive challenges exist, and how performance changes over time.
At the center of Neurotek is MOXO, our cloud-based cognitive assessment platform. MOXO combines scientifically validated assessment methodologies with real-world distractors and one of the world's largest proprietary cognitive performance datasets, enabling objective diagnostic support, deeper cognitive profiling, personalized treatment planning, and longitudinal monitoring.
Since 2014, more than 1.5 million MOXO assessments have been conducted across more than 50 countries. Our technology is supported by over 180 peer-reviewed publications and is used by clinicians, healthcare organizations, researchers, and institutions worldwide.
But our vision extends beyond assessment.
We believe cognitive performance should be measurable, understandable, and actionable at scale. By combining validated science, objective performance data, and a growing global cognitive baseline, Neurotek is building the intelligence layer that enables organizations to understand cognitive performance at both the individual and population level.
Our goal is simple: better cognitive data, better decisions, and better outcomes.
To make complete and objective cognitive performance intelligence available to every clinician, organization, educator and researcher, replacing subjective observation with the precision of science.
The people behind the measure.
Transformational CEO, seasoned entrepreneur, and business growth expert, Yaki Dayan uniquely blends international hi-tech business expertise with academic research, global EdTech leadership, and social impact entrepreneurship.
Yaki founded EdTech Israel (2014) and the Israel Education Summit (2016-2020) with the vision of transforming Israel into an EdTech nation. His contributions were recognized when he was named a Global EdTech Leader 2025 finalist by the prestigious US-based EdTech Digest Awards program.
Yaki holds a PhD in education from the University of Haifa (2014) and a BSc in Electronics Engineering from the Technion (1982).
In 2022, he took the helm at Neurotek, aiming to position it as a leader in digital cognitive measurement and assessment.
LinkedInClinical and academic oversight.
Sam Goldstein, Ph.D. is an Adjunct Assistant Professor at the University of Utah School of Medicine. He is Clinical Director of the Neurology Learning and Behavior Center.
Dr. Goldstein has authored over fifty trade and science texts, co-authored ten psychological tests, and serves as Editor in Chief of the Journal of Attention Disorders.
Prof. Luis A. Rohde, MD, PhD is Professor of Child and Adolescent Psychiatry at the Federal University of Rio Grande do Sul and Director of the ADHD Program at Hospital de Clínicas de Porto Alegre, Brazil. He is President of the International Association of Child and Adolescent Psychiatry and Allied Professions and a past member of the DSM-5 ADHD working group.
Prof. Rohde has published over 500 peer-reviewed articles and 50 book chapters and has been named a Highly Cited Researcher in Psychiatry and Psychology by Clarivate (2020-2022).
Mickey is a global EdTech and virtual learning pioneer. She is the co-founder of Connections Academy, a ground-breaking online school provider that launched in 2001 and now serves more than 110,000 K-12 students globally.
Mickey is Board Chair of Brooklyn Lab Charter School, Yellow Arrow Publishing, and Barbara J Dreyer Cares Foundation. She holds a BA from Yale, an MBA from NYU, and an MFA from Bennington.
Cesar A. Soutullo, MD, PhD, is John S. Dunn Endowed Professor at McGovern Medical School, and Vice Chair and Chief of Child & Adolescent Psychiatry, and Director of the ADHD Outpatient Program at the UTHealth Department of Psychiatry and Behavioral Sciences.
Dr. Soutullo's publications include over 104 original papers and 140 books, review papers or book chapters. He is listed as a top 0.2% author on ADHD worldwide.
Want to know more?
Tell us what you need to measure and who you need to measure it for. We will map the right solution and walk through the reports.